comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-28 11:15:37 Page View：68694

LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Websites selling Wegovy, Zepbound ingredients targeted by FDA
Next article： Bright Health sells Medicare Advantage business to Molina

comprehensive

Anesthesiologist group: stop taking Ozempic before surgery

EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

Latigo launches with $135 million for Vertex

DesmondPadhi,PharmD,interimCEO,Latigo(center),withLatigoboardchairNancyStagliano(left)andWestlakeVil

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

Long Covid research funding gets a major boost from NIH

NIHgaveaprojecttostudyandfindtreatmentsforlongCovidmoremoneythisweek.AdobeWASHINGTON—TheBidenadminis

comprehensive

explore

comprehensive

Long Covid research funding gets a major boost from NIH